KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.

导出 LinkOut

翻译打印收藏纠错

作者： Seon Rang,Woo ^[1] ; Yunhee,Ham ^[2] ; Wonyoung,Kang ^[3] ; Heekyoung,Yang ^[3] ; Sujong,Kim ^[4] ; Juyoun,Jin ^[3] ; Kyeung Min,Joo ^[5] ; Do-Hyun,Nam ^[2]

作者单位： Department of Neurosurgery, Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea ; Cancer Stem Cell Research Center, Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea. ^[1] Department of Neurosurgery, Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea ; Cancer Stem Cell Research Center, Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea ; Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea. ^[2] Department of Neurosurgery, Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea ; Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea. ^[3] Pharmaceutical Division, Komipharm International Co., Ltd., Seoul 429-450, Republic of Korea ; Graduate School of Biomedical Science & Engineering, Hanyang University, Seoul 133-791, Republic of Korea. ^[4] Cancer Stem Cell Research Center, Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea ; Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea ; Department of Anatomy and Cell Biology, Samsung Medical Center and Sungkyunkwan University School of Medicine, Seoul 135-710, Republic of Korea ; Center for Molecular Medicine, Samsung Biomedical Research Institute, Seoul 135-710, Republic of Korea. ^[5]

主题词动物(Animals);细胞凋亡(Apoptosis);亚砷酸盐类(Arsenites);DNA损伤(DNA Damage);达卡巴嗪(Dacarbazine);药物协同作用(Drug Synergism);胶质母细胞瘤(Glioblastoma);人类(Humans);小鼠(Mice);肿瘤复发, 局部(Neoplasm Recurrence, Local);辐射增敏药(Radiation-Sensitizing Agents);钠化合物(Sodium Compounds);端粒(Telomere);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)

DOI 10.1155/2014/747415

PMID 25295271

发布时间 2021-10-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览10

BioMed research international

2014年2014卷

747415页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.

BioMed research international

相似文献

BioMed research international

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.

BioMed research international

相似文献

BioMed research international

相关期刊

检索历史清除